Hjem › Ikke-småcellet lungekreft › Indiana › Fort Wayne
Kliniske studier for Ikke-småcellet lungekreft i Fort Wayne, IN
17 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Fort Wayne (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RekruttererFase 2/3
- Parkview Research Center /ID# 277651, Fort Wayne
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
RekruttererFase 1/2
- Parkview Comprehensive Cancer Center /ID# 271879, Fort Wayne
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- Parkview Regional Medical Center, Fort Wayne
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
RekruttererFase 3
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RekruttererFase 3
- Parkview Research Center at Parkview Regional Medical Center ( Site 0089), Fort Wayne
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekruttererFase 2
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RekruttererFase 3
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RekruttererFase 3
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RekruttererFase 2/3
- Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RekruttererFase 3
- Research Site, Fort Wayne
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekruttererFase 3
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
RekruttererFase 3
- Research Site, Fort Wayne
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RekruttererFase 1
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekruttererFase 1
- Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RekruttererFase 3
- Parkview Packnett Family Cancer Institute, Fort Wayne
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekruttererFase 1
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne
BostonGene and Exigent Genomic INsight Study
RekruttererObservasjonsstudie
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andre studier i Fort Wayne
- Eggstokkreft8 studier
- Kreft (alle typer)7 studier
- Kronisk lymfatisk leukemi7 studier
- Brystkreft7 studier
- Lungekreft6 studier
- Metastatisk kreft6 studier
- Endometriekreft5 studier
- Melanom4 studier
- Plateepitelcancer i hode og hals4 studier
- Tripelnegativ brystkreft4 studier
- Kolorektal kreft4 studier
- Multipelt myelom4 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.